secwatch / observer
PCVX Vaxcyte, Inc.
CIK 0001649094 50 ready 8-Ks latest August 5, 2026, 4:07 PM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (4)
Ready 8-Ks 50
Latest filing August 5, 2026, 4:07 PM ET
Top materiality 0.90
Event mix other_material ×22 · earnings ×18 · leadership ×7
Sentiment 16 pos · 0 neg · 34 neu
Latest earnings reported 2026-Q1
Executive change recent →

Recent 8-K filings for PCVX

Highest-materiality recent filing

Vaxcyte enters into Master Services Agreement with Lonza for manufacturing of VAX-24 and VAX-31 components

March 6, 2023, 6:59 PM ET other material materiality 0.90 neutral item 1.01 ◈ Material Agreements

Read filing →

Executive changes

Departed

Heath Lukatch

Director
PCVX · Vaxcyte, Inc.
Effective
2026-07-16
Successor
John Markels
Filed
July 15, 2026, 4:05 PM ET
On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.
Appointed

John Markels

Director
PCVX · Vaxcyte, Inc.
Effective
2026-07-16
Filed
July 15, 2026, 4:05 PM ET
Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026.
Appointed

Moncef Slaoui

Class II Director
PCVX · Vaxcyte, Inc.
Effective
2026-06-17
Filed
June 23, 2026, 4:09 PM ET
On June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Moncef Slaoui to the Board as a Class II director, which appointment became effective immediately.
Departed

Jacks Lee

Director
PCVX · Vaxcyte, Inc.
Effective
2026-06-17
Filed
June 23, 2026, 4:09 PM ET
On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of June 17, 2026.
Appointed

Dr. Olivier Brandicourt

Director
PCVX · Vaxcyte, Inc.
Effective
2025-05-01
Filed
May 1, 2025, 7:59 PM ET
On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.
Appointed

John P. Furey

Class II director
PCVX · Vaxcyte, Inc.
Effective
2024-07-02
Filed
July 2, 2024, 7:59 PM ET
the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed John P. Furey to the Board as a Class II director, which appointment became effective on July 2, 2024.
Appointed

Jacks Lee

Class II Director
PCVX · Vaxcyte, Inc.
Effective
2023-11-27
Filed
November 28, 2023, 6:59 PM ET
appointed Jacks Lee to the Board as a Class II director
Appointed

Elvia Cowan

Principal Accounting Officer
PCVX · Vaxcyte, Inc.
Effective
2023-01-01
Filed
December 12, 2022, 6:59 PM ET
On December 6, 2022, the Board of Directors of Vaxcyte, Inc. (the “Company”) appointed Elvia Cowan, its Senior Vice President, Finance, as the Company’s principal accounting officer, effective January 1, 2023.
Departed

Patrick Heron

Director
PCVX · Vaxcyte, Inc.
Effective
2021-09-16
Filed
September 20, 2021, 7:59 PM ET
On September 16, 2021, Patrick Heron, a director of the Vaxcyte, Inc. (the “Company”) and member of the Audit Committee, and Rob Hopfner, a director of the Company and member of the Nominating and Corporate Governance Committee (the “Nominating Committee”), both resigned as members of the Company’s Board of Directors (the “Board”), which resignations became effective on September 16, 2021.
Appointed

Teri Loxam

Director
PCVX · Vaxcyte, Inc.
Effective
2021-09-16
Filed
September 20, 2021, 7:59 PM ET
On September 16, 2021, upon recommendation of the Nominating Committee, the Board appointed Annie Drapeau and Teri Loxam to the Board as Class I directors, which appointments became effective on September 16, 2021.
Departed

Rob Hopfner

Director
PCVX · Vaxcyte, Inc.
Effective
2021-09-16
Filed
September 20, 2021, 7:59 PM ET
On September 16, 2021, Patrick Heron, a director of the Vaxcyte, Inc. (the “Company”) and member of the Audit Committee, and Rob Hopfner, a director of the Company and member of the Nominating and Corporate Governance Committee (the “Nominating Committee”), both resigned as members of the Company’s Board of Directors (the “Board”), which resignations became effective on September 16, 2021.
Appointed

Annie Drapeau

Director
PCVX · Vaxcyte, Inc.
Effective
2021-09-16
Filed
September 20, 2021, 7:59 PM ET
On September 16, 2021, upon recommendation of the Nominating Committee, the Board appointed Annie Drapeau and Teri Loxam to the Board as Class I directors, which appointments became effective on September 16, 2021.

Earnings & guidance

2026-Q1 EPS reported -$2.30 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event other_material

16 positive 0 negative 34 neutral

source · PCVX on sec.gov